Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Thousand Oaks Bio Completes $235 Million Round for CDMO Ops

publication date: Jan 14, 2022

Thousand Oaks Biopharma, headquartered in Nantong, completed a $235 million Series D financing to support its biologic CDMO operations. In 2017, TOBio was founded when it decided to integrate its core cell culture medium business, which was founded in 2011 as JSBio, with CDMO services, offering a one-stop solution from raw materials to complete CMC services. The company has global operations with production bases and R&D laboratories in Nantong, Shanghai, Lanzhou, Gansu and Los Angeles. The D round was completed last month. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China